Covered recipient · General Payments record
HENRY A GREENBLATT
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$2,604.11
- Reported across 72 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $715.28 | 15 |
| Education | $94.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $262.42 | 3 |
| GENZYME CORPORATION | $261.75 | 4 |
| E.R. Squibb & Sons, L.L.C. | $125.48 | 1 |
| LEO Pharma Inc. | $72.52 | 3 |
| Incyte Corporation | $51.97 | 3 |
| UCB, Inc. | $19.46 | 1 |
| Regeneron Healthcare Solutions, Inc. | $16.67 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.48 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101410887 | CMS |
| GENZYME CORPORATION | $125.00 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139615428 | CMS |
| GENZYME CORPORATION | $4.83 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139615416 | CMS |
| GENZYME CORPORATION | $125.00 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139615454 | CMS |
| GENZYME CORPORATION | $6.92 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139615432 | CMS |
| Incyte Corporation | $19.14 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141304899 | CMS |
| Incyte Corporation | $15.94 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141229301 | CMS |
| Incyte Corporation | $16.89 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141263767 | CMS |
| Janssen Biotech, Inc. | $147.34 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078459862 | CMS |
| Janssen Biotech, Inc. | $94.99 | 04/24/2024 | Education | Undisputed | 01/23/2026 | 1078459694 | CMS |
| Janssen Biotech, Inc. | $20.09 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078459906 | CMS |
| LEO Pharma Inc. | $21.86 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152632101 | CMS |
| LEO Pharma Inc. | $25.51 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152632103 | CMS |
| LEO Pharma Inc. | $25.15 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152632105 | CMS |
| Regeneron Healthcare Solutions, Inc. | $16.67 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114059762 | CMS |
| UCB, Inc. | $19.46 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143027740 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.